Bull or Bear Market… Doesn’t matter

Kyle Dennis’ new, 5 Min Strategy is poised to double Your Money Weekly!

Michael S. made 173% with Dollar Ace. So can you!


Secondary offerings can raise red flags in biotech stocks

Kyle DennisKyle Dennis ·

When a publicly traded company decides to raise money through a secondary offering, it should give you pause. Not all secondary offerings raise red flags in biotech and pharmaceutical stocks. Some companies need capital to operate like any other business. However, when a company goes back to the well time after time with secondary offerings, you may want to shy away from the stock.

Secondary offerings are the issuance of new shares of stock after a company has conducted its initial public offering (IPO). Companies generally conduct secondary offerings to raise capital. If a biotech or pharmaceutical company has a history of multiple secondary offerings, it may mean that its research and development for some treatments have failed. The company was burning cash for clinical trials, which may have been the reason for multiple secondary offerings. The extra shares dilute the stock, which can be detrimental to shareholder value.

If a company has some treatments currently being marketed because it could use earnings generated from those treatments to fund clinical trials. Therefore, if it’s conducting secondary offerings, that could be a red flag.

To see whether a company is issuing a secondary offering, analyze its SEC Form S-3 filing. Check out a snippet of InsmpireMD’s (NSPR) SEC Form S-3 filing.

secondary offerings

Source:  BamSEC

Final words

Secondary offerings could indicate the company is diluting the stock. That’s always dangerous to an investor. If you examine the company’s SEC filings and notice multiple secondary offerings, consider whether they change your opinion on the stock. It’s possible that you might want to wait until after any offering has passed before you consider playing it.


Kyle Dennis runs Kyle Dennis’ Biotech Breakouts (biotechbreakouts.com). He is an event-based trader, who prefers low-priced and small-cap biotech stocks.  

You may also like

Exclusive System Tracks Wall St. Insiders

“Dollar Ace Simply Exposes Information That Wall Street Wants To Keep Quiet” Said Kyle Dennis
“One member, Wesley M., has already reported 360%+ gains in just a few short days. Don’t miss this!”
(Reserve Access Now)

“What Recession?!” Jason Bond nets $55,060 in realized profit in One Day

After going 6 for 6 on profitable trades recently, we caught up with Jason to ask how he did it.
Check out Jason’s exclusive interview revealing this tightly guarded strategy. (Watch Now)

RagingBull.com Co-Founder, Jeff Bishop, Launches High Conviction Trade Service

“We listen to our clients and we give them EXACTLY what they want, so we designed a service to deliver 1 trade, 1 time a week, with a 100%+ PROFIT TARGET, directly to your inbox every Monday before the market opens. (Read More)

Be a Better Stock Trader, Starting Today

Get the expert insights, tips and strategies you need to optimize your trading skills and profiles